Biomarker News and Research

RSS

A biomarker is a biological molecule found in blood, other body fluids, or tissues that is a sign of a normal or abnormal process, or of a condition or disease. A biomarker may be used to see how well the body responds to a treatment for a disease or condition. Also called molecular marker and signature molecule.

SARS-CoV-2 infection causes specific kidney proximal tubular injury

SARS-CoV-2-associated acute kidney injury (AKI) is one of the more frequently encountered organ involvements in COVID-19 - in as many as 80% of critically ill patients, according to a recent study.

8 Jun 2020

Study identifies potential biomarker for prescreening donor's stem cells

A new study released today in STEM CELLS addresses a significant problem that has been confronting human mesenchymal stem cells (hMSCs) therapy.

8 Jun 2020

Kidney enzyme renalase a potential therapy for severe COVID-19

Researchers from Yale School of Medicine have discovered that a low blood level of an enzyme called renalase is associated with severe coronavirus disease 2019 (COVID-19).

7 Jun 2020

New approach helps identify protein biomarkers in the blood of COVID-19 patients

People respond very differently to infection with the novel coronavirus (SARS-CoV-2). While some patients develop no symptoms at all, others will develop severe disease and may even die. For this reason, there is an urgent need for 'biomarkers', quantifiable biological characteristics which could provide a reliable means of predicting disease progression and severity.

5 Jun 2020

HPV vaccines that work in the U.S. may not be effective in protecting other populations of women

A research team at Dartmouth's and Dartmouth-Hitchcock's Norris Cotton Cancer Center has found that the same vaccination programs that target human papillomavirus (hrHPV) strains in the United States may not be as effective in protecting other populations of women from the disease.

4 Jun 2020

27 protein biomarkers predict COVID-19 severity in patients

Some patients infected with the novel coronavirus may experience only mild symptoms, while others may need medical care due to severe illness. People who are at a high risk of developing severe coronavirus disease (COVID-19) include older adults and those with underlying health conditions. However, severe disease has also been seen in young people with no underlying disease.

4 Jun 2020

New detection platform may help speed up viral diagnosis

The prompt, precise, and massive detection of a virus is the key to combat infectious diseases such as Covid-19.

3 Jun 2020

Bruker introduces breakthrough MALDI-2 source on timsTOF fleX, and further innovations in CCS-enabled 4D proteomics on timsTOF

At the virtual ASMS 2020 Reboot conference, Bruker Corporation today announces a major advance in matrix-assisted laser desorption ionization (MALDI) with the launch of the world’s first commercial MALDI-2 post-ionization (PI) source, which is now available as an option on the timsTOF fleXTM ESI/MALDI mass spectrometer.

From Bruker Daltonics 3 Jun 2020

New detection platform for rapid diagnosis of infectious diseases

The prompt, precise, and massive detection of a virus is the key to combat infectious diseases such as Covid-19.

1 Jun 2020

Study compares cediranib plus olaparib and standard of care therapy for platinum-sensitive ovarian cancer

Results of the NRG Oncology phase III clinical trial NRG-GY004 indicated that the addition of the investigational agent cediranib to olaparib and standard platinum-based chemotherapy did not improve progression-free survival (PFS) outcomes for women with platinum-sensitive ovarian cancer; however, activity between the treatments was similar in patients.

30 May 2020

High-throughput analysis of blood plasma could help identify biomarkers for ALS

High-throughput analysis of blood plasma could aid in identification of diagnostic and prognostic biomarkers for amyotrophic lateral sclerosis (ALS), according to research from North Carolina State University.

29 May 2020

Targeted therapy tepotinib shows durable response in NSCLC patients with METex14 skipping mutation

Patients with advanced non-small cell lung cancer (NSCLC) and the MET exon 14 (METex14) skipping mutation had a 46.5% objective response rate to the targeted therapy drug tepotinib, as shown in a study published today in the New England Journal of Medicine and presented at the 2020 American Society of Clinical Oncology Annual Meeting ASCO20 Virtual Meeting (Abstract 9556 - Poster 322) by researchers from The University of Texas MD Anderson Cancer Center.

29 May 2020

Targeted therapy pralsetinib shows high response rates in patients with RET fusion-positive cancers

The targeted therapy pralsetinib appears to have high response rates and durable activity in patients with a broad variety of tumors harboring RET gene fusions, according to results from the international Phase I/II ARROW trial, led by researchers at The University of Texas MD Anderson Cancer Center.

29 May 2020

Blood test offers new opportunities to improve malarial control and elimination strategies

Plasmodium vivax is the most widespread malaria parasite worldwide, with up to two billion people at risk of infection.

29 May 2020

Combination therapy does not show superior efficacy in newly diagnosed myeloma

The combination of carfilzomib, lenalidomide, and dexamethasone (KRd) did not show superior efficacy in patients with newly diagnosed myeloma absent a high-risk disease prognosis, compared with the standard of care--bortezomib, lenalidomide, and dexamethasone (VRd).

29 May 2020

Researchers identify risk factors for fatty liver disease

Researchers at Massachusetts General Hospital have uncovered an unexpected connection between an imbalance of electrons in liver cells and many metabolic problems that increase the risk for conditions such as cardiovascular disease and fatty liver disease.

29 May 2020

Radiation and surgery do not prolong survival in newly diagnosed metastatic breast cancer

Up to now, women who present with a new diagnosis of breast cancer that is already in an advanced stage (stage IV) face an unanswered question about whether surgery and radiation to the tumor in the breast (local therapy) will prolong survival compared to the traditional treatment of systemic treatment alone.

29 May 2020

Biomarker News and Research

Further Reading

SARS-CoV-2 infection causes specific kidney proximal tubular injury

Study identifies potential biomarker for prescreening donor's stem cells

Kidney enzyme renalase a potential therapy for severe COVID-19

New approach helps identify protein biomarkers in the blood of COVID-19 patients

HPV vaccines that work in the U.S. may not be effective in protecting other populations of women

27 protein biomarkers predict COVID-19 severity in patients

New detection platform may help speed up viral diagnosis

Bruker introduces breakthrough MALDI-2 source on timsTOF fleX, and further innovations in CCS-enabled 4D proteomics on timsTOF

New detection platform for rapid diagnosis of infectious diseases

Study compares cediranib plus olaparib and standard of care therapy for platinum-sensitive ovarian cancer

High-throughput analysis of blood plasma could help identify biomarkers for ALS

Targeted therapy tepotinib shows durable response in NSCLC patients with METex14 skipping mutation

Targeted therapy pralsetinib shows high response rates in patients with RET fusion-positive cancers

Blood test offers new opportunities to improve malarial control and elimination strategies

Combination therapy does not show superior efficacy in newly diagnosed myeloma

Researchers identify risk factors for fatty liver disease

Radiation and surgery do not prolong survival in newly diagnosed metastatic breast cancer

Research provides new evidence for potential blood-based biomarker for Alzheimer's

Scientists use microneedle patches to extract the skin’s interstitial fluid

IgG antibodies reduce viral load of SARS-CoV-2

Event guide: 16th Clinical Biomarkers & CDx Summit Europe eBook

Latest eBooks

Industry Focus eBook - Analytical Chemistry (3rd edition)

Industry Focus eBook - Microbiome (1st edition)

Industry Focus eBook - Cell biology (5th edition)

Advancing degrader and proximity-based drug development

Designing fluidic architecture for scalable diagnostic platforms

Evaluating new approaches for rare disease genomics

Expanding access to NMR with the Fourier 80 Duo